Back to search results

Automated Insulin for Management of Intrapartum Glycemia

This study is looking at whether automated insulin delivery (AID) systems can help manage blood sugar during labor and delivery for pregnant individuals with type 1 diabetes (T1D). AID systems use a continuous glucose monitor (CGM) to automatically adjust insulin from a pump. Researchers will compare AID systems to intravenous (IV) insulin, which is the usual care. They want to see how AID affects the baby's first blood sugar level, your satisfaction with birth, and how well your blood sugar stays in a healthy range. You might be able to join if you are 18-55 years old, at least 34 weeks pregnant with a single baby, have had T1D for at least a year, and have been using an AID system since 28 weeks of pregnancy. The study is currently recruiting 150 participants.

Study design
This is an interventional study where participants will be randomly assigned to either use an automated insulin delivery (AID) system or receive intravenous (IV) insulin during labor and delivery. The study plans to enroll 150 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, the baby's first glucose value, is measured within 2 hours of birth.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06883344

Automated Insulin for Management of Intrapartum Glycemia

Recruiting
NAAges 18–55InterventionalTreatment
University of California, San Francisco
~150 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:Automated insulin delivery (AID) systemIntravenous (IV) insulin

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
First neonatal glucose value
Measured over Within 2 hours of birth

Conditions

Type 1 Diabetes (T1D)
Pregnancy
Pre-Gestational Diabetes

Explore related trials

PregnancyType 1 Diabetes Mellitus

Where it's being run

3 sites across 1 states
California3

Study leadership

  • Nasim Sobhani, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

DAPP Principal Investigator
[email protected]
(415) 307-9319
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Currently pregnant at ≥ 34 weeks
Known diagnosis of type 1 diabetes ≥ 1 year
Use of commercially available AID system since at least 28 weeks gestation
Singleton pregnancy
English- or Spanish-speaking

Exclusion

Multifetal gestation
Planned cesarean delivery
Use of medications known to interfere with glucose metabolism
Intrauterine fetal demise
Physical or psychological disease likely to interfere with the conduct of the study and/or the ability to participate in own healthcare

What this trial measures

  • First neonatal glucose valueWithin 2 hours of birth

    A primary clinical goal of intrapartum glycemic management is to minimize the likelihood of low neonatal glucose values (hypoglycemia).